Acclaro Medical Announces FDA Clearance of UltraClear® Cold Ablative Fractional 2910 nm Fiber Laser for Treatment of Benign Pigmented Lesions and Vascular Dyschromia
Acclaro Medical, a medical technology company that specializes in developing and delivering trailblazing solutions for medical aesthetics and surgical practitioners worldwide, today announced clearance by the U.S. Food and Drug Administration (FDA) for a new indication of the Company’s UltraClear® cold ablative fractional 2910 nm fiber laser.